The tumors disappeared entirely.
In the long human struggle against cancer, a new chapter is being written — not with chemicals that poison indiscriminately, but with a therapy that teaches the body's own defenses to recognize and destroy what does not belong. Fifteen patients with advanced, treatment-resistant head and neck cancers, having exhausted every conventional option, experienced complete tumor elimination after receiving amivantamab in an international trial. Presented at the American Society of Clinical Oncology in Chicago, the findings do not yet constitute a cure, but they represent something rarer and more fragile: a door reopened for those who believed it had closed forever.
- Fifteen patients with aggressive, recurring cancers that had resisted every standard treatment saw their tumors vanish entirely — a word oncologists rarely allow themselves to use.
- The drug operates on three simultaneous fronts, blocking tumor growth, stripping cancer's immune defenses, and mobilizing the body's own cells to attack — a complexity that makes its simplicity of delivery, a subcutaneous injection every three weeks, all the more striking.
- More than 40% of the 102-patient international trial saw measurable tumor reduction, with median survival around twelve months for people the medical system had largely run out of answers for.
- One patient, Carl Walsh of Britain, regained the ability to eat and speak normally as his tumors receded — a restoration of capacities that conventional treatment had stripped away.
- Researchers are urging caution: larger trials are needed to confirm efficacy and map the full safety profile before amivantamab can become a standard option rather than a rare exception.
Fifteen people entered a clinical trial carrying the weight of exhausted options. Their head and neck cancers had already survived chemotherapy, immunotherapy, and every conventional intervention. Then they received amivantamab — and their tumors disappeared.
The findings, drawn from a 102-patient study across 11 countries, were presented at the American Society of Clinical Oncology's annual meeting in Chicago. More than a third of all participants saw significant tumor reduction. Fifteen achieved complete elimination — a term oncologists deploy with deliberate care. The drug works on three fronts at once: blocking the proteins that drive cancer growth, dismantling the biological shields tumors use to hide from the immune system, and activating immune cells to seek out and destroy malignant tissue. It is administered as a subcutaneous injection every three weeks, outpatient and relatively simple.
For patients with treatment-resistant cancers — particularly those not driven by HPV — the response rates were especially notable. Carl Walsh, a British participant, described a quiet transformation: as his tumors shrank, he recovered the ability to eat normally and regained meaningful function in his speech. These were not abstract statistics. They were the return of ordinary life.
Median survival in the trial reached approximately twelve months — a figure that carries different weight when the alternative was no remaining treatment path. Amivantamab already holds approval for certain lung cancers and is under investigation for brain, stomach, and other cancer types. Still, researchers are measured in their optimism. Larger studies must confirm what these early numbers suggest and clarify the drug's full safety profile before it can move from promising exception to established standard. The door has opened — how wide it swings depends on what comes next.
Fifteen people with advanced head and neck cancer walked into a clinical trial with few options left. They had already exhausted the standard treatments—chemotherapy, immunotherapy, the conventional arsenal. Their tumors were aggressive, recurring, resistant. Then they received an experimental injection called amivantamab, and something unexpected happened: the tumors disappeared entirely.
The results came from an international study spanning 11 countries, involving 102 patients total with some of the most difficult cancers to treat. Researchers presented the findings on Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago. What they found was striking enough to reshape how doctors think about treating these patients. More than a third of all participants saw their tumors shrink significantly. Fifteen achieved complete elimination—a word oncologists use carefully, because it means the cancer was gone.
The drug works through a mechanism that sounds almost elegant in its complexity. Amivantamab operates on three fronts simultaneously. It blocks the proteins that fuel cancer growth. It dismantles the tumor's defenses against the immune system—the biological shields that allow cancer cells to hide from the body's own defenders. And it activates those defenders, summoning immune cells to recognize and attack the malignant tissue. The treatment comes as a subcutaneous injection every three weeks, simple enough that patients can receive it in an outpatient setting.
Forty-two percent of the trial participants experienced measurable tumor reduction. The median survival observed was around twelve months, a figure that carries particular weight when you consider the alternative: these were patients for whom the medical system had largely run out of answers. For people with treatment-resistant cancers, especially those not driven by HPV infection, the response rates were particularly promising. One British participant, Carl Walsh, reported a transformation after beginning the therapy. As his tumors shrank, he regained the ability to eat normally and recovered significant function in his speech—a restoration of basic human capacities that chemotherapy and conventional immunotherapy had taken from him.
Yet researchers are cautious about what comes next. The results are encouraging, they say, but larger studies are needed to confirm that amivantamab truly works as well as these early numbers suggest, and to understand its full safety profile. The drug already carries approval for certain lung cancers and is being investigated in brain, stomach, and other lung cancer variants. The broader context matters too: health systems worldwide are racing to develop new immunotherapies and personalized cancer vaccines, betting that the future of oncology lies in training the immune system to recognize and destroy cancer cells rather than poisoning them with chemicals.
What happened in this trial represents a narrow but real opening for patients who thought the door had closed. Whether it becomes a standard option or remains a specialized tool for a small population depends on what larger studies reveal in the months and years ahead.
Notable Quotes
Carl Walsh regained the ability to eat normally and recovered significant speech function after his tumors shrank— Trial participant, reported by researchers
The Hearth Conversation Another angle on the story
Why does it matter that these fifteen patients had already failed other treatments?
Because it changes what we're measuring. A new drug that helps treatment-naive patients is interesting. A drug that works when everything else has failed is a different kind of story—it's about people who were told there was nothing left to try.
The mechanism sounds complex. Does that complexity matter to the patient receiving the injection?
Not in the moment, no. But it matters to whether the drug might work against other cancers. If it works by three different routes, it's harder for tumors to develop resistance. That's why researchers are testing it in brain and stomach cancers now.
Twelve months median survival—is that good?
For patients with advanced, treatment-resistant head and neck cancer, it's significant. But the word "median" matters. Some lived longer. Some shorter. And we don't know yet if amivantamab extends survival compared to doing nothing, or if it just improves quality of life in the time patients have left.
Carl Walsh regained his ability to eat and speak. Is that the real story here?
It might be. The tumor shrinkage is what gets measured in trials, but what matters to a person is whether they can eat, speak, swallow, live without pain. Those are the things that disappeared when the cancer came. Getting them back—that's the human measure of success.
Why the caution about larger studies? Fifteen complete responses sounds pretty clear.
Because fifteen is a small number in a trial of 102. And because pharmaceutical history is full of drugs that looked miraculous in early trials and didn't hold up. Caution isn't pessimism—it's the price of not overselling hope.